Latest News about FDA
Recent news which mentions FDA
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
August 08, 2024
From Benzinga
Five Out Of Six Studies On MDMA Show Positive Results, Yet FDA Approval Still Faces Hurdles
August 07, 2024
Tickers
NEWS
From Benzinga
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
August 07, 2024
From Benzinga
Senators Press FDA To Approve MDMA As PTSD Treatment, Stressing US Vets' Suicide Rates As Aug 11 Decision Looms
August 06, 2024
Tickers
NEWS
From Benzinga
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety
August 05, 2024
Tickers
IXHL
From Benzinga
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
August 05, 2024
From Benzinga
From Benzinga
Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines
August 02, 2024
Tickers
NEWS
From Benzinga
From Benzinga
Art Installation Near White House Urges FDA To Approve MDMA-Assisted Therapy For Veterans As Decision Time Looms
July 29, 2024
Tickers
NEWS
From Benzinga
From Benzinga
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks
July 29, 2024
From Benzinga
Harris Vs. Trump: Will Cannabis Rescheduling Survive Biden's Exit? Analyst On Potential GOP Victory
July 24, 2024
From Benzinga
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy
July 23, 2024
From Benzinga
Allarity Therapeutics Hit By SEC Notice Related Disclosures Of Once Lead Cancer Program
July 22, 2024
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.